ClinicalTrials.gg
CompletedNCT04036292Updated Nov 22, 2021Results posted

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

A Phase 3 interventional study of OC-01 (varenicline) nasal spray and Placebo (vehicle) nasal spray in Dry Eye Disease (DED), sponsored by Oyster Point Pharma, Inc.. Completed at 22 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2021-11-22.

Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
758
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.

Enrollment
Largest of 13
758 · median 60
Started
2019
with 1 other
Phase 3
4 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
4 of 13
Oyster Point Pharma, Inc.

Among the 13 studies testing varenicline in Dry Eye Syndromes, this one has the largest enrollment, is one of 2 that started in 2019, is one of 4 in phase 3, and was the 4th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing varenicline in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.

Read the detailed description

This was a Phase 3, multicenter, randomized, controlled, double-masked (including subjects, Investigators, study site personnel, and Sponsor personnel) study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray 0.6 mg/mL and 1.2 mg/mL in adult participants with DED. The study randomized 758 subjects at least 22 years of age with a physicians' diagnosis of DED and meeting all other study eligibility criteria to receive OC-01 (varenicline) nasal spray or placebo twice daily (BID) for 28 days with three additional long-term follow-up visits at 6 weeks, 6 months, and 12 months. Participants who terminated from the study during the treatment period were asked to complete safety assessments (if the participants agree) prior to study exit. Participants who were terminated early from the study were not replaced

03

Conditions studied

  • Dry Eye Disease (DED)

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to Visit 1

Exclusion criteria

Exclusion Criteria:

  • Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months or refractive surgery (e.g. laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1.
  • Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with dry eye disease are allowed.
  • Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
  • Have a known to any of the procedural agents or study drug components
  • Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
758 participants (actual)

Study arms

  • Active comparator
    OC-01 Low Dose, 0.6 mg/mL

    OC-01 (varenicline) nasal spray, 0.6 mg/ML

    Drug: OC-01 (varenicline) nasal spray

  • Active comparator
    OC-01 High Dose, 1.2 mg/mL

    OC-01 (varenicline) nasal spray, 1.2 mg/ML

    Drug: OC-01 (varenicline) nasal spray

  • Placebo comparator
    Placebo (vehicle) nasal spray

    Placebo (vehicle) nasal spray

    Drug: Placebo (vehicle) nasal spray

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)

    The primary endpoint was the percentage of subjects who achieve ≥10 mm improvement in Schirmer's Test Score from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)]

Secondary outcomes

  1. Mean Change From Baseline in Eye Dryness Score in CAE at Week 4 at 5 Minutes

    Change in Eye Dryness Score Eye from baseline in CAE at 4 Weeks at 5 minutes post treatment. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.

    Time frame: 28 Days [Visit 1 (baseline) and Visit 4a (28 days)]

  2. Mean Change From Baseline in Eye Dryness Score From Baseline to Day 28

    Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.

    Time frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)]

  3. Mean Change Form Baseline in Schirmer's Test Score From Baseline to Day 28

    Change in Schirmer test score from baseline to Day 28. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)]

  4. Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 2

    Chang in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better otucome.

    Time frame: 14 Days [Visit 1 (baseline) and Visit 3 (14 days)]

  5. Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 1

    Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.

    Time frame: 7 Days [Visit 1 (baseline) and Visit 2 (7 days)]

07

Results

Posted Nov 22, 2021

Participant flow

Participant flow — Overall Study
MilestoneOC-01 Low Dose 0.6 mg/mL BID for 28 DaysOC-01 High Dose 1.2 mg/mL BID for 28 DaysPlacebo BID for 28 Days
Started260246252
Completed239212228
Not completed213424

Outcome measures

PrimaryPercent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)

The primary endpoint was the percentage of subjects who achieve ≥10 mm improvement in Schirmer's Test Score from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
28 Days [Visit 1 (baseline) and Visit 4b (28 days)]
Reported as:
Count of participants · Participants
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)
ParticipantsOC-01 Low Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo (Vehicle) Nasal Spray
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)12312170
SecondaryMean Change From Baseline in Eye Dryness Score in CAE at Week 4 at 5 Minutes

Change in Eye Dryness Score Eye from baseline in CAE at 4 Weeks at 5 minutes post treatment. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.

Time frame:
28 Days [Visit 1 (baseline) and Visit 4a (28 days)]
Reported as:
Least squares mean · mm
Mean Change From Baseline in Eye Dryness Score in CAE at Week 4 at 5 Minutes
mmOC-01 Low Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
Mean Change From Baseline in Eye Dryness Score in CAE at Week 4 at 5 Minutes-10.3 ± 1.62-9.0 ± 1.75-7.4 ± 1.74
SecondaryMean Change From Baseline in Eye Dryness Score From Baseline to Day 28

Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.

Time frame:
28 Days [Visit 1 (baseline) and Visit 4b (28 days)]
Reported as:
Least squares mean · mm
Mean Change From Baseline in Eye Dryness Score From Baseline to Day 28
mmOC-01 Low Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
Mean Change From Baseline in Eye Dryness Score From Baseline to Day 28-19.8 ± 1.54-22.2 ± 1.61-15.4 ± 1.57
SecondaryMean Change Form Baseline in Schirmer's Test Score From Baseline to Day 28

Change in Schirmer test score from baseline to Day 28. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
28 Days [Visit 1 (baseline) and Visit 4b (28 days)]
Reported as:
Least squares mean · mm
Mean Change Form Baseline in Schirmer's Test Score From Baseline to Day 28
mmOC-01 Low Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
Mean Change Form Baseline in Schirmer's Test Score From Baseline to Day 2811.3 ± 0.6111.5 ± 0.646.3 ± 0.61
SecondaryMean Change From Baseline in Eye Dryness Score in the Study Eye at Week 2

Chang in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better otucome.

Time frame:
14 Days [Visit 1 (baseline) and Visit 3 (14 days)]
Reported as:
Least squares mean · mm
Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 2
mmOC-01 Low Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 2-16.5 ± 1.38-17.9 ± 1.45-12.7 ± 1.41
SecondaryMean Change From Baseline in Eye Dryness Score in the Study Eye at Week 1

Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.

Time frame:
7 Days [Visit 1 (baseline) and Visit 2 (7 days)]
Reported as:
Least squares mean · mm
Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 1
mmOC-01 Low Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 1-15.7 ± 1.33-15.4 ± 1.40-13.3 ± 1.35

Adverse events

Collected over Adverse Events were collected from the first dose of study drug administration until the final study visit at Visit 7. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OC-01 Low Dose, 0.6 mg/mL0/260 (0%)5/260 (1.9%)253/260 (97.3%)
OC-01 High Dose, 1.2 mg/mL2/245 (0.8%)12/245 (4.9%)243/245 (99.2%)
Placebo1/251 (0.4%)9/251 (3.6%)158/251 (62.9%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventOC-01 Low Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
Coronavirus infectionInfections and infestations0/2601/2451/251
Diabetic gangreneInfections and infestations0/2601/2450/251
GangreneInfections and infestations0/2601/2450/251
BradycardiaCardiac disorders0/2601/2450/251
Coronary artery diseaseCardiac disorders0/2601/2450/251
Myocardial infarctionCardiac disorders0/2601/2450/251
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2601/2450/251
Cerebrovascular accidentNervous system disorders0/2601/2450/251
Transient ischemic attackNervous system disorders0/2601/2450/251
Deep vein thrombosisVascular disorders0/2601/2450/251
Most frequent other events
Showing 10 of 86
Most frequent other events
EventOC-01 Low Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
SneezingRespiratory, thoracic and mediastinal disorders247/260237/24573/251
CoughRespiratory, thoracic and mediastinal disorders49/26054/2455/251
Throat irritationRespiratory, thoracic and mediastinal disorders35/26044/2455/251
Instillation site irritationGeneral disorders21/26036/2453/251
NasopharyngitisInfections and infestations9/26016/24514/251
Nasal congestionRespiratory, thoracic and mediastinal disorders10/2605/24512/251
conjunctival hyperaemiaEye disorders12/26011/2457/251
Visual acuity reducedEye disorders9/2609/24511/251
Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders9/2608/2459/251
EpistaxisRespiratory, thoracic and mediastinal disorders9/2606/2452/251

Baseline characteristics

Subjects in the ITT population

Age, Continuous
Age, Continuous(years)OC-01 Low Dose 0.6 mg/mL BID for 28 DaysOC-01 High Dose 1.2 mg/mL BID for 28 DaysPlacebo (Vehicle) Nasal Spray BID for 28 DaysTotal
Mean59.6 ± 12.7658.4 ± 13.0358.4 ± 13.2958.8 ± 13.02
Sex: Female, Male
Sex: Female, Male(Participants)OC-01 Low Dose 0.6 mg/mL BID for 28 DaysOC-01 High Dose 1.2 mg/mL BID for 28 DaysPlacebo (Vehicle) Nasal Spray BID for 28 DaysTotal
Female194181201576
Male666551182
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OC-01 Low Dose 0.6 mg/mL BID for 28 DaysOC-01 High Dose 1.2 mg/mL BID for 28 DaysPlacebo (Vehicle) Nasal Spray BID for 28 DaysTotal
Hispanic or Latino273736100
Not Hispanic or Latino233209216658
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OC-01 Low Dose 0.6 mg/mL BID for 28 DaysOC-01 High Dose 1.2 mg/mL BID for 28 DaysPlacebo (Vehicle) Nasal Spray BID for 28 DaysTotal
Race — American Indian or Alaska Native1269
Race — Asian117523
Race — Black or African American27352991
Race — Native Hawaiian or other Pacific Islander2013
Race — White219200211630
Race — Other0202
Region of Enrollment
Region of Enrollment(participants)OC-01 Low Dose 0.6 mg/mL BID for 28 DaysOC-01 High Dose 1.2 mg/mL BID for 28 DaysPlacebo (Vehicle) Nasal Spray BID for 28 DaysTotal
United States260246252758
Baseline Schirmer's Test Score (mm)
Baseline Schirmer's Test Score (mm)(mm)OC-01 Low Dose 0.6 mg/mL BID for 28 DaysOC-01 High Dose 1.2 mg/mL BID for 28 DaysPlacebo (Vehicle) Nasal Spray BID for 28 DaysTotal
Mean5.1 ± 2.955.4 ± 2.934.9 ± 2.895.1 ± 2.93
08

Study locations

22 sites
  • Phoenix
    Phoenix, Arizona 85032, United States
  • New Port Beach
    Newport Beach, California 92663, United States
  • Fort Collins
    Fort Collins, Colorado 80528, United States
  • Waterbury
    Waterbury, Connecticut 06708, United States
  • Delray Beach
    Delray Beach, Florida 33484, United States
  • Indianapolis
    Indianapolis, Indiana 46290, United States
  • Louisville
    Louisville, Kentucky 40206, United States
  • Raynham
    Raynham, Massachusetts 02767, United States
  • Las Vegas
    Las Vegas, Nevada 89052, United States
  • Raleigh
    Raleigh, North Carolina 27603, United States
  • Shelby
    Shelby, North Carolina 28150, United States
  • Fargo
    Fargo, North Dakota 58103, United States
  • Cranberry Township
    Cranberry Township, Pennsylvania 16066, United States
  • Warwick
    Warwick, Rhode Island 02842, United States
  • Sioux Falls
    Sioux Falls, South Dakota 57108, United States
  • Nashville
    Nashville, Tennessee 37210, United States
  • Austin
    Austin, Texas 78731, United States
  • Houston
    Houston, Texas 77025, United States
  • San Antonio
    San Antonio, Texas 78209, United States
  • San Antonio
    San Antonio, Texas 78229, United States
  • Layton
    Layton, Utah 84041, United States
  • Lynchburg
    Lynchburg, Virginia 24502, United States
09

References and documents

Publications

  • Nijm LM, Zhu D, Hemphill M, Blemker GL, Hendrix LH, Kabat AG, Gibson AA. Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials. Ophthalmol Ther. 2023 Feb;12(1):355-364. doi: 10.1007/s40123-022-00607-7. Epub 2022 Nov 18. PubMed 36401081 ↗
  • Wirta D, Vollmer P, Paauw J, Chiu KH, Henry E, Striffler K, Nau J; ONSET-2 Study Group. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. Ophthalmology. 2022 Apr;129(4):379-387. doi: 10.1016/j.ophtha.2021.11.004. Epub 2021 Nov 10. PubMed 34767866 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Apr 2020, 8 months.

Results were first posted in Nov 2021, 1 year 7 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 8 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2019
First posted
Jul 29, 2019
StartActual
Jul 23, 2019
Primary completionActual
Apr 10, 2020
CompletionActual
Feb 5, 2021
Results first posted
Nov 22, 2021
Last update
Nov 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04036292
Responsible party
Sponsor
First posted
Jul 29, 2019
Start date
Jul 23, 2019
Primary completion
Apr 10, 2020
Completion
Feb 5, 2021
Results posted
Nov 22, 2021
Last update
Nov 22, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion